GlassScriptPhysician profile
Reena Ramesh Kabaria
NPI 1659711547
$5,632.87
in general payments reported to CMS, 2019-2025
36 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,259 · 2020: $171 · 2021: $319 · 2022: $1,100 · 2023: $1,550 · 2024: $431 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,781 · Travel and Lodging: $2.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,781.26 |
| Travel and Lodging | $2.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,211.29 | 2019-2025 | Ams 700, Rezum Generator, Spaceoar Vue System - 10ml |
| Teleflex LLC | $944.65 | 2022-2025 | Urolift, Barrigel |
| Coloplast Corp | $622.28 | 2019-2025 | Titan, Speedicath |
| Cook Medical LLC | $481.15 | 2022-2025 | Litho 150, Cook, Fiber Dust |
| Astellas Pharma US INC | $383.78 | 2019-2024 | Xtandi |
| Procept Biorobotics Corporation | $373.90 | 2023-2025 | Aquabeam Robotic System |
| Medtronic, INC. | $192.53 | 2023 | Interstim |
| Dendreon Pharmaceuticals LLC | $178.87 | 2019-2023 | Provenge |
| Pfizer INC. | $146.19 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $131.13 | 2023-2025 | Orgovyx, Gemtesa |
| Ethicon US, LLC | $108.66 | 2019 | |
| Endo USA, INC. | $98.17 | 2024-2025 | Xiaflex, Aveed |
| Abbvie INC. | $95.76 | 2019-2025 | |
| Blue Earth Diagnostics | $69.46 | 2019 | |
| Neotract INC. | $49.12 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $43.56 | 2019-2020 | |
| Calyxo, INC. | $41.15 | 2024-2025 | Cvac Aspiration System |
| Olympus America INC. | $40.56 | 2019-2025 | Soltive |
| Ferring Pharmaceuticals INC. | $40.47 | 2025 | Adstiladrin |
| Alnylam Pharmaceuticals INC. | $36.18 | 2023 | Oxlumo |
| Urovant Sciences INC | $32.77 | 2022 | |
| Ambu INC. | $30.97 | 2021 | |
| Myriad Genetic Laboratories, INC. | $29.26 | 2025 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $25.68 | 2025 | |
| Amgen INC. | $25.54 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $22.42 | 2022 | |
| Axonics, INC. | $21.80 | 2023 | Bulkamid, Axonics |
| Smith+Nephew, INC. | $20.60 | 2025 | Stravix |
| Verity Pharmaceuticals INC. | $20.39 | 2023 | Trelstar |
| Laborie Medical Technologies Corp. | $19.96 | 2023 | |
| Hollister Incorporated | $18.87 | 2022 | |
| Becton, Dickinson and Company | $17.62 | 2022 | |
| Therapeuticsmd, INC. | $17.08 | 2019 | |
| Dentsply Ih INC. | $16.72 | 2022 | |
| Janssen Biotech, INC. | $12.99 | 2019 | |
| Zyla Life Sciences, INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Kabaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.